Takara traded at 1,088.00 this Tuesday August 16th, increasing 3.00 or 0.28 percent since the previous trading session. Looking back, over the last four weeks, Takara gained 5.84 percent. Over the last 12 months, its price fell by 19.88 percent. Looking ahead, we forecast Takara to be priced at 1,054.98 by the end of this quarter and at 951.29 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Nippon Suisan Kaisha 579.00 -1.00 -0.17% -0.17%
Nisshin Seifun 1,618.00 2.00 0.12% -8.64%
Meiji Holdings 6,860.00 10.00 0.15% 3.78%
Sapporo Group 3,005.00 49.00 1.66% 28.86%
Asahi Group 4,794.00 8.00 0.17% -6.50%
Kirin Holdings 2,248.00 13.00 0.58% 16.48%
Takara 1,088.00 3.00 0.28% -19.88%
Kikkoman Corporation 8,920.00 70.00 0.79% 25.81%
Nichirei 2,518.00 -14.00 -0.55% -2.82%
Shiseido 5,527.00 -28.00 -0.50% -22.81%

Indexes Price Day Year
JP225 28864 4.33 0.02% 5.25%

TAKARA HOLDINGS INC. is Japan-based brewing holding company. The Company operates in three business segments. The TAKARA SHUZO CO., LTD segment is engaged in the manufacture and sales of alcohol beverages, food seasonings and other businesses. The TAKARA SHUZO INTERNATIONAL CO., LTD segment exportr liquors from Japan, manufactures and sells liquors overseas, and conducts Japanese food wholesale business. The TAKARA BIO INC segment involves in the manufacture and sale of research reagents, physical and chemical equipment, mushrooms, the provision of contract research services on gene therapy and cell therapy.